Global Methylphenidate Drug Market Size, Share and Trends Analysis Report, By Product (Tablet and Capsule), By Application (Children and Adults), Forecast (2022-2028)

The global methylphenidate drug market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Methylphenidate drugs is known as stimulants, that improves attention span, remains mentally active, and manages behavioral issues. This drug is majorly used to treat ADHD (attention deficit hyperactivity disorder). Methylphenidate drug market is predicted to grow significantly over the forecast period, due to the rising prevalence of ADHD disorder and the growing preference for less expensive and effective generic ADHD medications. According to the Centers for Disease Control and Prevention, as of 2019, approximately 6.1 million of the total population of the US have been diagnosed with ADHD. Furthermore, male population is more likely to be diagnosed with ADHD as compared to female, which is estimated around 12.9% compared to 5.6%.

Increasing various general public and governments awareness programs and initiatives towards the mental health issues is another major factor which is driving the growth of the market. The expanding number of people suffering from a variety of mental health illnesses, including ADHD has gained the traction of government globally. For instance, in March 2022, the Department of Health and Human Services (HHS) announced nearly $35 million in funding opportunities to strengthen and expand community mental health services and suicide prevention programs for America’s children and young adults through the Substance Abuse and Mental Health Services Administration (SAMHSA) and the Office of Minority Health (OMH). This declaration is part of a new administration-wide effort to address the country’s mental health issue.

Additionally, NHS England established a five-year mental health plan. The government had implemented this plan from 2020 to 2021, with a total investment of $1.27 billion. Furthermore, rise in investments from of market participants catering to develop non-stimulant medications for ADHD/ hyperactivity disorder is expected to propel the growth of the market during the forecast period. For instance, in April 2021, Supernus ADHD drug received an approval from USFDA. It is first non-stimulant medication developed in a past decade.

Market Coverage

• The market number available for – 2022-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Indication
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- JanssenGlobal Services, LLC, Rhodes Pharmaceuticals L.P., Noven Pharmaceuticals, Inc., Ironshore Pharmaceuticals Inc., Lannett.   among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Methylphenidate Drug Market Report by Segment

By Type

• Tablet
• Capsule

By Indication

• Children
• Adults

Global Methylphenidate Drug Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America

Middle East & Africa